OncoCyte Corporation (OCX)
After hours:
| Previous close | 3.0500 |
| Open | 3.0800 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.9200 - 3.0800 |
| 52-week range | 2.0800 - 5.1000 |
| Volume | |
| Avg. volume | 62,570 |
| Market cap | 39.158M |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Oncocyte Reports First Quarter 2024 Financial Results
Conference Call on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ETIRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc.On track to ship research use only (RUO) GraftAssure™ transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q
- GlobeNewswire
Oncocyte to Announce First Quarter 2024 Financial Results
Conference Call and Webcast on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ETIRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, after U.S. market close. The company will host a conference call and webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and highlights. In
- GlobeNewswire
PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Oncocyte Corporation’s Chief Executive Officer, Josh Riggs, as the company works to disrupt the mature diagnostics marketplace with a nimble, capital-light approach to growth. Oncocyte (Nasdaq: OCX) has developed and is preparing to commercialize precision tests in the transplant and oncology markets. The Company’s transplant diagnostic tests, VitaGraft™ and GraftAssure™, measure the
